Shuttle Pharma said it entered a securities purchase agreement for a public offering expected to raise about USD 3.5 million in gross proceeds. The offering includes 2.24 million shares of common stock and pre-funded warrants to buy 4.76 million shares. E.F. Hutton is acting as exclusive placement agent. Shuttle Pharma said it expects to use up to USD 1.5 million of the net proceeds for future marketing efforts, with the remainder for working capital and general corporate purposes. The offering is being made pursuant to a registration statement on Form S-1 available at www.sec.gov.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-009551), on March 10, 2026, and is solely responsible for the information contained therein.